STOCKS TELEGRAPH

Tag: NeuroBo Pharmaceuticals Inc.

  • NeuroBo Pharmaceuticals Inc. (NRBO) stock Soars After Hours. Any Reasons?

    On March 18, NeuroBo Pharmaceuticals Inc. (NRBO) stock surged up in the after-hours while there is no news from the company. The latest news from the company dates back to March 15, 2022.

    During the regular trading session, the stock traded in the green with a gain of 2.87%. NRBO closed the session at $0.84 while 2.13 million shares exchanged hands. Following this, the stock’s bullish roll leaped up at 28.57% in the after-hours. Hence, the stock was trading at a price of $1.08 per share in the after-hours while the volume of shares traded was 1.94 million.

    The clinical-stage biopharmaceutical company, NeuroBo Pharmaceuticals Inc. was founded in 2017. Currently, the company has a market capitalization of $22.34 million with its 26.59 million outstanding shares.

    NRBO stock Movement

    On March 15, the company announced the appointment of Danamarie Belpulsi to its Scientific Advisory Board.

    Source: DB4C

    Thus, after having a decent gain on March 15, the stock fell under profit booking on the following day. On March 17, the stock resumed a mild bullish course which continued into March 18’s regular session. The bullishness outpoured into a huge gain in the after-hours on Friday. With no new announcement, the stock seems to have gained on external factors. Social media discussions and stock sentiment seem to have caused the stock to surge up in the after hours.

    In the past five days, NRBO has added 11.14% while its stands at a year-to-date loss of 31.15%. Moreover, the stock declined by a huge 82.35% last year.

    Recent Developments

    The recently added Dr. Belpulsi is currently, Medical Director at ICON plc, and has extensive experience in infectious diseases, cardiology, and neurology among many others.

    Previously, on January 28, the company announced having appointed D. Gordon Strickland to its Board of Directors along with the Chair of Audit Committee. With over 35 years of experience in executive leadership roles, Mr. Gordon was most recently, the Chairman of Apex Corporations.

    NRBO’s Q3 2021 Highlights

    In the third quarter of 2021, NRBO incurred a net loss of $3.5 million or $0.16 on a diluted share basis. Comparatively, the company had a net loss of $3.1 million or $0.19 per share in the year-ago period.

    Furthermore, the company ended the quarter with cash and cash equivalents of $7.0 million on September 39, 2021.

  • Here’s What you Should Know about Surging Premarket Stock of NeuroBo Pharmaceuticals, Inc. (NRBO)

    Here’s What you Should Know about Surging Premarket Stock of NeuroBo Pharmaceuticals, Inc. (NRBO)

    NeuroBo Pharmaceuticals, Inc. (NRBO) is a leading innovative biotherapeutics company engaged in the development of treatments for neuropathic and neurodegenerative diseases. One of the lead pipeline candidates of the company is ANA001 is in Phase 2/3 clinical trial for the treatment of patients with COVID-19. NB-01 in Phase 2 trial for treating painful diabetic neuropathy patients. NB-02 for treating Alzheimer’s and Gemcabene for treating dyslipidemia and acute treatment for COVID-19.

    The price of NRBO stock during the regular trading on January 21, 2022, was $1.12 with a decline of 8.12%. At last check in the premarket on January 24, 2022, the stock was significantly up by 8.93%.

    NRBO: Key Financials

    On November 15, 2021, NRBO reported its financial results for the third fiscal quarter ended September 30, 2021. Some of the key updates are as follows

    Net Loss per Share

    Basic and diluted net loss for third-quarter 2021 was $3.5 million, or $0.16 per share compared to the same period of 2020 when it was $3.1 million, or $0.19 per share.

    Assets

    The total current assets of the company in Q3 2021 were $7.84 million.

    NRBO: Events and Happenings

    On November 4, 2021, NRBO reported about the appointment of Gil Price as President and CEO of the company. He had already served in eminent positions in leading global pharmaceutical industries. On October 13, 2021, NRBO reported that the safety data of patients in Phase 2/3 studies of ANA001 was reviewed by a Data Monitoring Committee. The results recommended the continuation of the clinical trials without any further adjustment.

    On October 5, 2021, NRBO reported about the closure of its direct registered offering of 4,307,693 shares of the common stock and warrants of the company acquired at a public price of $3.25 per share.  The gross proceeds from the acquisition were approximately $12.7 million used for corporate purposes.

    Conclusion

    NRBO stock decreased phenomenally 62% from the last six months due to the challenges faced by the industry because of the pandemic. The current premarket surge in the stock is the result of uncertain factors as there is no recent activity or news by the company. The analysts are predicting that the company’s potential drug pipeline is generating positive outcomes which will increase the investment options for the company in the coming days.